RECRUITING

Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry (Dexcom Global Registry)

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

"To evaluate the use of the Dexcom CGM System when used according to approved commercial labeling during standard clinical use and its impact on intended users in a real-world setting"

Official Title

Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry

Quick Facts

Study Start:2024-02-28
Study Completion:2028-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06483945

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:2 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Meets Dexcom CGM System Indications for Use (IFU) per approved commercial labeling
  2. * Has at least one HbA1C (Hemoglobin a1c) measurement within three (3) months prior to the Dexcom CGM System use start date that is at least three (3) months after any prior CGM use
  3. * Subject is willing and able to use Dexcom CGM System according to approved product labeling
  4. * Subject is willing and able to complete applicable patient reported outcome assessments/ surveys
  5. * Subject is willing and able to comply with the protocol
  6. * Subject is willing and able to comply with provider requirements for at least two provider encounters per year according to applicable clinical practice guidelines
  7. * Subject or the subject's legally authorized representative must provide written informed consent prior to any study-related data collection or be enrolled under an IRB/EC approved waiver of consent
  1. * Is contraindicated for a Dexcom CGM System per approved commercial labeling
  2. * In the Investigator's opinion, the subject is not considered to be a suitable candidate

Contacts and Locations

Study Contact

Stayce Beck, PhD
CONTACT
858 704 2428
PTL1000088@dexcom.com
Kathleen Hurst
CONTACT
858 704 2428
PTL1000088@dexcom.com

Study Locations (Sites)

Institute of Endocrinology Diabetes, Health & Hormones
Stockbridge, Georgia, 30281
United States
Palm Research Center
Las Vegas, Nevada, 89148
United States

Collaborators and Investigators

Sponsor: DexCom, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-02-28
Study Completion Date2028-06-30

Study Record Updates

Study Start Date2024-02-28
Study Completion Date2028-06-30

Terms related to this study

Additional Relevant MeSH Terms

  • Diabetes